NCT02108743

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: American Medical Association Foundation · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if dynamic hyperinflation seen in patients with idiopathic pulmonary artery hypertension (iPAH) improves with albuterol therapy.

Detailed description

Only a few small studies have evaluated the relationship between iPAH, expiratory flow limitation, and exercise dyspnea. While not all patients with iPAH demonstrate airway involvement, those who demonstrate dynamic hyperinflation (DH), defined as a variable and temporary increase in end-expiratory lung volume, report increased dyspnea with exertion on maximal testing. There is a continued need for adjuvant therapy in iPAH, and bronchodilators have the potential to ameliorate dyspnea during exercise, which could lead to improved quality of life in this disabling condition. This study will investigate the presence of airway involvement in this population as measured by dynamic hyperinflation, and if there is any improvement in function with the use of inhaled albuterol.

Conditions

• Idiopathic Pulmonary Arterial Hypertension.

Interventions

Type	Name	Description
DRUG	Albuterol.	2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
DRUG	Normal saline placebo	Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.

Timeline

• Start date: 2014-06-01
• Primary completion: 2016-07-01
• Completion: 2016-10-01
• First posted: 2014-04-09
• Last updated: 2015-12-30

Locations

1 site across 1 country: United States